Zoledronic acid: Multiplicity of use across the cancer continuum

Expert Review of Anticancer Therapy

Volumn 11, Issue 7, 2011, Pages 1001-1014

  Lipton, Allan ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

antiresorptive; pharmacodynamics; pharmacokinetics; safety; skeletal related events; zoledronic acid

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; DENOSUMAB; DOXORUBICIN; ETIDRONIC ACID; GOSERELIN; IBANDRONIC ACID; LETROZOLE; MULTIVITAMIN; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DENSITY; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHILL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EARLY CANCER; EDEMA; FATIGUE; FEVER; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY DISEASE; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; NAUSEA; NONHUMAN; OVERALL SURVIVAL; POLYPHARMACY; PRIMARY TUMOR; PROSTATE CANCER; RECOMMENDED DRUG DOSE; RISK REDUCTION; SINGLE DRUG DOSE; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

EID: 79961035423     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.71     Document Type: Article

References (99)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2(8), 584-593 (2002). (Pubitemid 37328925)
2. Coleman RE. Skeletal complications of malignancy. Cancer 80(8 Suppl.), 1588-1594 (1997). (Pubitemid 27444031)
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
4. Costa L, Badia X, Chow E, Lipton A, Wardley A. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer 16(8), 879-889 (2008).
5. Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 113(6), 1438-1445 (2008).
6. Weinfurt KP, Li Y, Castel LD et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann. Oncol. 16(4), 579-584 (2005). (Pubitemid 40613323)
7. Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat. Rev. 34(2), 183-192 (2008). (Pubitemid 351384327)
8. Lipton A. Should bisphosphonates be utilized in the adjuvant setting for breast cancer? Breast Cancer Res. Treat. 122(3), 627-636 (2010).
9. Lattouf JB, Saad F. Bone complications of androgen deprivation therapy: screening, prevention, and treatment. Curr. Opin. Urol. 20(3), 247-252 (2010).
10. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 14(5), 1718-1729 (1996). (Pubitemid 26134232)
11. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J. Clin. Oncol. 19(14), 3306-3311 (2001). (Pubitemid 32642182)
12. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98(8), 1735-1744 (2003). (Pubitemid 37238631)
13. Morgan GJ, Davies FE, Gregory WM et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376(9757), 1989-1999 (2010).
14. Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 10(1), 52-62 (2005). (Pubitemid 40171251)
15. McCloskey EV, Dunn JA, Kanis JA, MacLennan ICM, Drayson MT. Longterm follow-up of a prospective, doubleblind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br. J. Haematol. 113(4), 1035-1043 (2001). (Pubitemid 32634773)
16. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94(19), 1458-1468 (2002).
17. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J. Natl Cancer Inst. 96(11), 879-882 (2004). (Pubitemid 38807610)
18. Kohno N, Aogi K, Minami H et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J. Clin. Oncol. 23(15), 3314-3321 (2005).
19. Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebocontrolled trials. Cancer 88(5), 1082-1090 (2000). (Pubitemid 30127670)
20. Body JJ, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. 14(9), 1399-1405 (2003). (Pubitemid 37185286)
21. Body JJ, Diel IJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled Phase III studies. Br. J. Cancer 90(6), 1133-1137 (2004). (Pubitemid 38496803)
22. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol. 11(1), 59-65 (1993). (Pubitemid 23059975)
23. Tubiana-Hulin M, Beuzeboc P, Mauriac L et al. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]. Bull. Cancer 88(7), 701-707 (2001). (Pubitemid 32831138)
24. Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J. Intern. Med. 246(1), 67-74 (1999). (Pubitemid 29327354)
25. Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132-5139 (2010).
26. Rosen LS, Gordon DH, Dugan W Jr et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100(1), 36-43 (2004). (Pubitemid 37553537)
27. Henry D, von Moos R, Vadhan-Raj S et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Presented at: The Joint ECCO 15-34th ESMO Multidisciplinary Congress. Berlin, Germany, 20-24 September 2009 (Abstract 20LBA).
28. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst. Rev. 3, CD003474 (2005).
29. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768), 813-822 (2011).
30. Fleisch H. Bisphosphonates: Mechanisms of action Endocr. Rev. 19 1 80-100 1998 (Pubitemid 29122075)
31. Fleisch H. Bisphosphonates: mechanisms of action. Endocr. Rev. 19(1), 80-100 (1998).31 Juillard A, Falgayrac G, Cortet B et al. Molecular interactions between zoledronic acid and bone: an in vitro Raman microspectroscopic study. Bone 47(5), 895-904 (2010).
32. Chen T, Berenson J, Vescio R et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J. Clin. Pharmacol. 42(11), 1228-1236 (2002). (Pubitemid 35205058)
33. Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol. 21(16), 3150-3157 (2003). (Pubitemid 46606297)
34. Zometa (zoledronic acid) injection [package insert]. Novartis Pharmaceuticals Corporation, NJ, USA (2008).
35. Skerjanec A, Berenson J, Hsu C et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J. Clin. Pharmacol. 43(2), 154-162 (2003). (Pubitemid 36125942)
36. Dunford JE, Kwaasi AA, Rogers MJ et al. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: timedependent inhibition of human farnesyl pyrophosphate synthase. J. Med. Chem. 51(7), 2187-2195 (2008). (Pubitemid 351503274)
37. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone. Miner. Res. 13(4), 581-589 (1998). (Pubitemid 28163009)
38. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J. Bone. Miner. Res. 9(5), 745-751 (1994). (Pubitemid 24130477)
39. Raikkonen J, Monkkonen H, Auriola S, Monkkonen J. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells. Biochem. Pharmacol. 79(5), 777-783 (2010).
40. Monkkonen H, Auriola S, Lehenkari P et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br. J. Pharmacol. 147(4), 437-445 (2006). (Pubitemid 43292286)
41. Schran H, Ravera C, Skerjanec A, Boisclair M. Regular dosing of zoledronic acid maintains suppression of osteolysis in patients with malignant bone disease. Presented at: The International Bone and Mineral Society Davos Workshops: Bone Biology and Therapeutics. Davos, Switzerland, 9-14 March 2008 (Abstract 199).
42. Major P, Lortholary A, Hon J et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. 19(2), 558-567 (2001). (Pubitemid 32112871)
43. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, doubleblind, comparative trial. Cancer J. 7(5), 377-387 (2001). (Pubitemid 33759002)
44. Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100(12), 2613-2621 (2004). (Pubitemid 38715767)
45. Lipton A, Cook R, Saad F et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113(1), 193-201 (2008). (Pubitemid 351976401)
46. Hirsh V, Major PP, Lipton A et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J. Thorac. Oncol. 3(3), 228-236 (2008). (Pubitemid 351654321)
47. Body J-J, Cook R, Costa L et al. Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumors and poor prognostic features. Presented at: The IX International Meeting on Cancer Induced Bone Disease. Arlington, VA, USA, 28-31 October 2009 (Abstract 71).
48. Xgeva (denosumab) injection [package insert]. Amgen Inc., CA, USA (2010)
49. Gnant M, Mlineritsch B, Luschin- Ebengreuth G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 9(9), 840-849 (2008).
50. Brufsky AM, Bosserman LD, Caradonna RR et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin. Breast Cancer 9(2), 77-85 (2009).
51. de Boer R, Bundred N, Eidtmann H et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-up. Presented at: The 33rd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-12 December 2010 (Poster P5-11-01).
52. Llombart A, Frassoldati A, Paija O et al. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up. Presented at: The American Society of Clinical Oncology 2009 Breast Cancer Symposium. San Francisco, CA, USA, 8-10 October 2009 (Abstract 213).
53. Brufsky A, Harker WG, Beck JT et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow-up. Presented at: The 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9-13 December 2009 (Abstract 4083).
54. Hershman DL, McMahon DJ, Crew KD et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J. Clin. Oncol. 26(29), 4739-4745 (2008).
55. Shapiro CL, Halabi S, Hars V et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur. J. Cancer 47(5), 683-689 (2011).
56. Hershman DL, McMahon DJ, Crew KD et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J. Clin. Endocrinol. Metab. 95(2), 559-566 (2010).
57. Singh S, Cuzick J, Edwards R et al. Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II).Breast Cancer Res. Treat. 106(Suppl. 1), S9 (2007) (Abstract 28).
58. Van Poznak C, Hannon RA, Mackey JR et al. Prevention of aromatase inhibitorinduced bone loss using risedronate: the SABRE trial. J. Clin. Oncol. 28, 967-975 (2010).
59. Lester JE, Dodwell D, Purohit OP et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin. Cancer Res. 14(19), 6336-6342 (2008).
60. Ellis GK, Bone HG, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J. Clin. Oncol. 26(30), 4875-4882 (2008).
61. Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res. 12(6), 214 (2010).
62. Boissier S, Ferreras M, Peyruchaud O et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60(11), 2949-2954 (2000). (Pubitemid 30395820)
63. Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br. J. Cancer 88(10), 1631-1640 (2003). (Pubitemid 36713793)
64. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J. Bone Miner. Res. 15(11), 2211-2221 (2000).
65. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br. J. Cancer 84(8), 1126-1134 (2001). (Pubitemid 32448513)
66. Ottewell PD, Deux B, Monkkonen H et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin. Cancer Res. 14(14), 4658-4666 (2008).
67. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol. Cancer Ther. 8(10), 2821-2832 (2009).
68. Aft R, Naughton M, Trinkaus K et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, Phase 2 trial. Lancet Oncol. 11(5), 421-428 (2010).
69. Greenberg S, Park JW, Melisko ME et al. Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): updated results. Presented at: The 46th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 4-8 June 2010 (Abstract 1002).
70. Rack B, Juckstock J, Genss EM et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res. 30(5), 1807-1813 (2010).
71. Solomayer EF, Gebauer G, Hirnle P et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Cancer Res. 69(Suppl. 2), 170S-171S (2009) (Abstract 2048).
72. Braun S, Vogl FD, Naume B et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353(8), 793-802 (2005). (Pubitemid 41215488)
73. Diel IJ, Jaschke A, Solomayer EF et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann. Oncol. 19(12), 2007-2011 (2008).
74. Powles T, Paterson A, McCloskey E et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 8(2), R13 (2006).
75. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 43(7), 650-656 (2004). (Pubitemid 39563937)
76. Gnant M, Mlineritsch B, Stoeger H et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 12(7), 631-641 (2011).
77. Coleman RE, Thorpe HC, Cameron D et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04).Presented at: The 33rd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-12 December 2010 (Abstract S4-S5).
78. Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360(7), 679-691 (2009).
79. Eidtmann H, de Boer R, Bundred N et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann. Oncol. 21(11), 2188-2194 (2010).
80. Coleman R, Bundred NJ, de Boer R et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Presented at: The 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9-13 December 2009 (Abstract 4082).
81. Coleman RE, Winter MC, Cameron D et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br. J. Cancer 102, 1099-1105 (2010).
82. Lipton A, Chapman JW, Demers L et al. Elevated bone resorption predicts shorter recurrence-free survival for bone metastasis in breast cancer. Presented at: Primary Therapy of Early Breast Cancer 11th International Conference. St. Gallen, Switzerland, 11-14 March 2009 (Abstract 244).
83. Lipton A, Chapman JW, Demers L et al. Elevated bone resorption predicts shorter recurrence-free survival for bone metastasis in breast cancer: NCIC CTG MA.14. J. Clin. Oncol. (2011) (In Press).
84. Coleman R, Burkinshaw R, Winter M et al. Zoledronic acid. Expert Opin. Drug Saf. 10(1), 133-145 (2010).
85. Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J. Clin. Endocrinol. Metab. 95(9), 4380-4387 (2010).
86. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, doubleblind, comparative trial. Cancer J. 7(5), 377-387 (2001). (Pubitemid 33759002)
87. Weitzman R, Sauter N, Eriksen EF et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients - May 2006. Crit. Rev. Oncol. Hematol. 62(2), 148-152 (2007). (Pubitemid 46575276)
88. Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 22(10), 1479-1491 (2007). (Pubitemid 351229318)
89. Badros A, Weikel D, Salama A et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J. Clin. Oncol. 24(6), 945-952 (2006). (Pubitemid 46638849)
90. Hoff AO, Toth BB, Altundag K et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J. Bone. Miner. Res. 23(6), 826-836 (2008). (Pubitemid 351768801)
91. McArthur HL, Estilo C, Huryn J et al. Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC).J. Clin. Oncol. 26(Suppl.), 523S (2008) (Abstract 9588).
92. Fehm T, Beck V, Banys M et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol. Oncol. 112(3), 605-609 (2009).
93. Fusco V, Loidoris A, Colella G, Vescovi P, Campisi G. Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment. Breast 19(5), 432-433; author reply 433-434 (2010).
94. Ibrahim T, Barbanti F, Giorgio-Marrano G et al. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study. Oncologist 13(3), 330-336 (2008). (Pubitemid 351679909)
95. Vahtsevanos K, Kyrgidis A, Verrou E et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonaterelated osteonecrosis of the jaw. J. Clin. Oncol. 27(32), 5356-5362 (2009).
96. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonateinduced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral. Oncol. 44(9), 857-869 (2008).
97. Badros A, Terpos E, Katodritou E et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J. Clin. Oncol. 26(36), 5904-5909 (2008).
98. Dimopoulos MA, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann. Oncol. 20(1), 117-120 (2009).
99. Ripamonti CI, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann. Oncol. 20(1), 137-145 (2009).